MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2022 International Congress

    An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy

    A. Pujol, A. Bosch, I. Dijkstra, S. Kemp, Y. Jaspers, S. Verdés, S. Fourcade, C. Guilera, M. Leal-Julià, A. Onieva, V. Vasireddy, SW. Clark, D. Anderson, K. Kozarsky (Barcelona, Spain)

    Objective: SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate delivering a functional copy of the human ABCD1 gene that is in development…
  • 2022 International Congress

    Nutritional Status of Patients with Parkinson’s Disease: Report from Indonesian Tertiary Referral Hospital

    SS. Musthafa, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: This study aimed to describe and determine the prevalence of nutritional status in outpatient Parkinson’s Disease (PD) patients. Background: Parkinson’s disease is the most…
  • 2022 International Congress

    Clinical Manifestations of Metabolic Syndrome in Parkinson’s Disease – Report from Indonesia Tertiary Referral Hospital

    DA. Soraya, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: The study aims to determine the prevalence of metabolic syndrome and related factors in Parkinson's disease (PD). Background: Parkinson's disease is a neurodegenerative disorder,…
  • 2022 International Congress

    Sex differences in vascular risk factors for Parkinson’s disease

    K. Tsutsumi, E. Shah, A. Siddiqui, I. Attaripour (Orange, USA)

    Objective: Our aim is to illustrate the incidence of vascular risk factors (VRF) in a cohort of patients with confirmed Parkinson's disease (PD) and characterize…
  • 2022 International Congress

    GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

    B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)

    Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal…
  • 2022 International Congress

    Designing a multi-arm multi-stage trial for Parkinson’s

    M-L. Zeissler, M. Burnell, T. Barber, Y. Ben-Shlomo, R. Chapman, C. Clarke, C. Counsell, M. Edwards, R. Ellis-Doyle, C. Gonzales-Robles, A. Jewell, G. Mills, J. Rudiger, D. Salathiel, S. Whipps, A. Whone, T. Foltynie, C. Carroll, R. Barker, J. Carpenter (Plymouth, United Kingdom)

    Objective: The Edmond J Safra ACT-PD initiative (EJS ACT-PD) is developing the first multi-arm multi-stage (MAMS) platform trial for potential disease modifying approaches for Parkinson’s…
  • 2022 International Congress

    Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease

    C. Gonzalez-Robles, J. Ahmed, C. Bale, R. Chapman, S. Clegg, E. Deeson, R. Ellis-Doyle, V. Greaves, J. Handley, E. Henderson, K. Matthews, S. Medd-Phillips, L. Miller, G. Mills, J. Rudiger, ML. Zeissler, C. Carroll, T. Foltynie, S. Gandhi, J. Duffen (London, United Kingdom)

    Objective: The Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (PD) initiative (EJS ACT-PD) aims to accelerate the identification of disease modifying treatment for…
  • 2022 International Congress

    Longitudinal Exercise is Associated with Reduced Hospitalization Risk in Parkinson’s Disease

    G. Kannarkat, M. Rafferty, S. Luo, H. Liu, K. Mills (Baltimore, USA)

    Objective: To determine if longitudinal exercise and physical therapy (PT) use is associated with reduced risk of hospital encounter in individuals with Parkinson’s disease (iwPD).…
  • 2022 International Congress

    Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework

    J. Anzures-Cabrera, A. Monnet, G. Pagano (Welwyn Garden City, United Kingdom)

    Objective: To show how the estimand framework can be used to improve design of clinical trials testing treatments in early-stage Parkinson’s disease (PD). Background: The…
  • 2022 International Congress

    IkT-148009 as a potential disease-modifying therapy in PD

    M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)

    Objective: Modeling Parkinson’s disease in mice suggests c-Abl activation is required for PD initiation and progression, and therefore inhibition of c-Abl could be a strategy…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley